Compounded Peptide Policy Announcement Expected by Year-End, per APC CEO

An official policy announcement enabling the temporary sale of compounded peptides is "highly likely" before year-end from either the FDA or the White House, according to Alliance for Pharmacy Compounding CEO Scott Brunner.
Key takeaways from the interview highlight several structural regulatory catalysts:
- Federal policy action is reportedly advancing with backing from incoming health leadership, signaling a near-term shift toward temporary access frameworks.
- Compounding pharmacies would likely require an estimated two to three months of operational preparation following formal guidance before commercial distribution begins.
- Domestic Active Pharmaceutical Ingredient (API) capacity remains constrained and will require time to scale to meet broader commercial volumes.
- Implementation timelines will balance interim access provisions against formal, multi-year administrative rulemaking and enforcement guardrails.
The anticipated regulatory pathway represents a major operational tailwind for compounding facilities and digital healthcare platforms such as $HIMS seeking formal access to peptide distribution.